Skip to Main Content
Contribute Try STAT+ Today

Results released Monday from a Phase 2 study of a chronic cough treatment being developed by Bellus Health exceeded the expectations of financial analysts and boost the company’s chances of eventual approval after an earlier trial of the drug had failed.

Bellus said in a press release it expects to meet with the Food and Drug Administration in the second quarter of 2022 and to begin a Phase 3 study of the treatment in the second half of 2022. Roberto Bellini, Bellus’ CEO, said the company is “extremely pleased” with the “compelling” results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment